The effects of adenosine A(1) receptor antagonism in patients with acute decompensated heart failure and worsening renal function: the REACH UP study.

[1]  P. Ponikowski,et al.  Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decom , 2011, Journal of the American College of Cardiology.

[2]  Gary S Francis,et al.  Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. , 2009, Journal of the American College of Cardiology.

[3]  M. Givertz,et al.  Role of adenosine antagonism in the cardiorenal syndrome. , 2008, Cardiovascular therapeutics.

[4]  C. O'connor,et al.  The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. , 2008, Journal of cardiac failure.

[5]  M. Metra,et al.  Worsening renal function in patients hospitalised for acute heart failure: Clinical implications and prognostic significance , 2008, European journal of heart failure.

[6]  R. Starling,et al.  Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? , 2008, Journal of the American College of Cardiology.

[7]  B. Massie,et al.  The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. , 2007, Journal of the American College of Cardiology.

[8]  John G F Cleland,et al.  Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. , 2007, Journal of cardiac failure.

[9]  H. Dittrich,et al.  The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. , 2007, Journal of cardiac failure.

[10]  B. Massie,et al.  Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study. , 2007, Journal of the American College of Cardiology.

[11]  A. Rigby,et al.  Effects of applying a standardised management algorithm for moderate to severe renal dysfunction in patients with chronic stable heart failure , 2007, European journal of heart failure.

[12]  D. Boison.  Adenosine and Epilepsy: From Therapeutic Rationale to New Therapeutic Strategies , 2005, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[13]  C. O'connor,et al.  Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. , 2004, Journal of the American College of Cardiology.

[14]  C. O'connor,et al.  The prognostic importance of different definitions of worsening renal function in congestive heart failure. , 2002, Journal of cardiac failure.

[15]  M. Fisher,et al.  Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. , 2000, Journal of the American College of Cardiology.

[16]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .